| Title: |
Assessment Of Early Changes In Spectral Domain-Optical Coherence Tomography After Initiation Of Treatment With Intravitreal Aflibercept (Eylea) Over A 12-Week Period For Patients With Neovascular Age-Related Macular Degeneration: A Multicenter French Study (Start) ; Retina |
| Authors: |
KOROBELNIK, Jean-Francois; SOUIED, Eric H.; OUBRAHAM, Hassiba; RAZAVI, Sam; MAUGET-FAYSSE, Martine; SAVEL, Helene; CHENE, Genevieve; WOLF, Sebastian |
| Publication Year: |
2021 |
| Subject Terms: |
Aflibercept; Central retinal thickness; Intravitreal injection; Intraretinal edema; Intraretinal cysts; Neovascular age-related macular degeneration; Retinal pigment epithelium; Spectral-domain optical coherence tomography; Subretinal fluid; Sciences du Vivant [q-bio]/Santé publique et épidémiologie |
| Description: |
PURPOSE: To assess early changes in spectral-domain optical coherence tomography during the loading phase with intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration. METHODS: In this prospective, open-label, single-arm, multicenter study, patients with neovascular age-related macular degeneration, who were antivascular endothelial growth factor treatment-naïve, received three monthly initial doses of intravitreal aflibercept 2 mg. The primary outcome was the proportion of patients with dry spectral-domain optical coherence tomography at 12 weeks, defined as an absence of intraretinal edema, intraretinal cysts, subretinal fluid, and subretinal pigment epithelium fluid. RESULTS: Fifty eyes of 50 patients were investigated. At 12 weeks, 34.0% (17/50) had dry spectral-domain optical coherence tomography. Marked reductions were observed for all other spectral-domain optical coherence tomography parameters. The mean macular central thickness fell significantly from 463.2 ± 184.3 µm at baseline to 288.9 ± 76.8 µm at Week 12 (P < 0.0001). The mean best-corrected visual acuity also improved significantly from 61.0 ± 16.0 letters at baseline to 66.6 ± 19.0 letters at Week 12 (P = 0.0006). CONCLUSION: The anatomic and functional outcomes improved over the 12-week study period. All outcome variables peaked after the third aflibercept injection, confirming the benefit of three initial doses. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1097/iae.0000000000002910 |
| Availability: |
https://oskar-bordeaux.fr/handle/20.500.12278/27008; https://hdl.handle.net/20.500.12278/27008; https://doi.org/10.1097/iae.0000000000002910 |
| Rights: |
open |
| Accession Number: |
edsbas.7C541D8E |
| Database: |
BASE |